UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): May 30, 2013
CATALYST PHARMACEUTICAL PARTNERS, INC.
(Exact Name Of Registrant As Specified In Its Charter)
| Delaware |
001-33057 |
76-0837053 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 355 Alhambra Circle Suite 1500 Coral Gables, Florida |
33134 | |
| (Address of principal executive offices) | (Zip Code) |
| Registrant’s telephone number, including area code: | (305) 529-2522 |
Not Applicable
Former Name or Former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07 Submission of Matters to a Vote of Security Holders
On May 30, 2013, Catalyst Pharmaceutical Partners, Inc. (the “Company”) held its Annual Meeting of Stockholders at the Hyatt Regency Coral Gables, 50 Alhambra Plaza, Coral Gables, Florida. The final voting results on the matters considered at the meeting are as follows:
| 1. | Election of Directors: |
| Name |
Votes For | Votes Withheld | Broker Non-Votes | |||
| Patrick J. McEnany |
17,855,170 | 263,730 | 15,151,838 | |||
| Philip H. Coelho |
17,822,170 | 296,730 | 15,151,838 | |||
| Hubert E. Huckel |
17,800,055 | 318,845 | 15,151,838 | |||
| Charles B. O’Keeffe |
17,852,216 | 266,684 | 15,151,838 | |||
| David S. Tierney |
17,855,770 | 263,130 | 15,151,838 |
| 2. | Approval, on an advisory basis, of the compensation of the Company’s named executive officers: |
| Votes For |
Votes Against |
Votes Abstained |
Broker Non-Votes | |||
| 17,604,563 |
420,034 | 94,303 | 15,151,838 |
| 3. | Selection, on an advisory basis, of the frequency of “say-on-pay” votes: |
| One Year |
Two Years |
Three Years |
Abstain |
Broker Non-Votes | ||||
| 11,366,380 |
281,389 | 6,178,514 | 292,617 | 15,151,838 |
| 4. | Ratification of the selection of Grant Thornton, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013: |
| Votes For |
Votes Against |
Votes Abstained | ||
| 33,043,182 |
153,011 | 74,545 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Catalyst Pharmaceutical Partners, Inc. | ||
| By: | /s/ Alicia Grande | |
| Alicia Grande Vice President, Treasurer and Chief Financial Officer | ||
Dated: June 3, 2013